TheraRadar
Landscape → Oncology

Myelofibrosis Clinical Trial Landscape

Data updated: May 20, 2026

278 clinical trials tracked since 2008

Myelofibrosis is being studied across 278 clinical trials registered since 2008, with 109 programs currently active. The competitive pipeline includes 15 active Phase 3 trials, 62 active Phase 2 trials, and 48 active Phase 1 trials. Top industry sponsors include Novartis, Bristol-Myers Squibb, Chia Tai Tianqing Pharmaceutical Group Co., Ltd..

109 active
/
278 total (since 2008)
48
Phase 1 Active
123 total
62
Phase 2 Active
162 total
15
Phase 3 Active
34 total
2
Phase 4 Active
3 total

Top Industry Sponsors

Sorted by active Active Done Failed
Novartis 4 9 6
Bristol-Myers Squibb 4 5 1
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 4 3 2
Incyte Corporation 3 4 2
Chengdu Zenitar Biomedical Technology Co., Ltd 3 1 0

+ 10 more sponsors — see full table below

Featured Phase 3 Trials

NCT07357727 RECRUITING
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Novartis Pharmaceuticals n=460
NCT03165734 ACTIVE NOT RECRUITING
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Swedish Orphan Biovitrum n=407
NCT04562389 ACTIVE NOT RECRUITING
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
Karyopharm Therapeutics Inc n=353
NCT06351631 RECRUITING
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
Merck Sharp & Dohme LLC n=400
NCT05198960 RECRUITING
AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms
University Hospital, Brest n=1,308

+ 29 more Phase 3 trials — see full database below

Myelofibrosis — Trials Started by Year (last 10 years)

2016
13
2017
15
2018
11
2019
16
2020
17
2021
33
2022
14
2023
11
2024
16
2025
12
2026
22

TheraRadar.com

Full Trial Database

Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.

Top Sponsors (all-time)

Novartis
19
Bristol-Myers Squibb
10
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
9
Incyte Corporation
9
Chengdu Zenitar Biomedical Technology Co., Ltd
4
Karyopharm Therapeutics Inc
3
AbbVie
5
Geron Corporation
4
iOnctura
2
GSK
2

Active Trials by Phase

Phase 1
48
Phase 2
62
Phase 3
15
Phase 4
2

Enrollment Size Distribution

1-50
143
51-200
87
201-500
31
501-1k
2
1k+
3

All Industry Sponsors

Sorted by active Active Done Failed
Novartis 4 9 6
Bristol-Myers Squibb 4 5 1
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 4 3 2
Incyte Corporation 3 4 2
Chengdu Zenitar Biomedical Technology Co., Ltd 3 1 0
Karyopharm Therapeutics Inc 3 0 0
AbbVie 2 2 1
Geron Corporation 2 2 0
iOnctura 2 0 0
GSK 2 0 0
Telios Pharma, Inc. 2 0 0
Prelude Therapeutics 1 1 0
Disc Medicine, Inc 1 0 0
Ajax Therapeutics, Inc. 1 0 0
Newave Pharmaceutical Inc 1 0 0
NCT07357727 RECRUITING
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Novartis Pharmaceuticals n=460
NCT03165734 ACTIVE NOT RECRUITING
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Swedish Orphan Biovitrum n=407
NCT07539779 NOT YET RECRUITING
Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis
Nanfang Hospital, Southern Medical University n=196
NCT04562389 ACTIVE NOT RECRUITING
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
Karyopharm Therapeutics Inc n=353
NCT06351631 RECRUITING
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
Merck Sharp & Dohme LLC n=400
NCT05198960 RECRUITING
AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms
University Hospital, Brest n=1,308
NCT07317700 RECRUITING
A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis
Chengdu Zenitar Biomedical Technology Co., Ltd n=105
NCT03480360 ACTIVE NOT RECRUITING
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
Dartmouth-Hitchcock Medical Center n=21
NCT04468984 ACTIVE NOT RECRUITING
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
AbbVie n=330
NCT04603495 ACTIVE NOT RECRUITING
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
Novartis Pharmaceuticals n=430
NCT04576156 ACTIVE NOT RECRUITING
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
Geron Corporation n=327
NCT04064060 RECRUITING
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Celgene n=665
NCT06479135 RECRUITING
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Kartos Therapeutics, Inc. n=600
NCT06468033 RECRUITING
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
PharmaEssentia n=150
NCT04717414 ACTIVE NOT RECRUITING
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
Celgene n=313
NCT04472598 COMPLETED
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
AbbVie n=252
NCT04551066 TERMINATED
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
Incyte Corporation n=252
NCT04551053 TERMINATED
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
Incyte Corporation n=177
NCT03952039 COMPLETED
An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
Celgene n=202
NCT03755518 TERMINATED
A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
Celgene n=38
NCT04617028 COMPLETED
Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis
Suzhou Zelgen Biopharmaceuticals Co.,Ltd n=105
NCT04173494 COMPLETED
A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)
Sierra Oncology LLC - a GSK company n=195
NCT01428635 COMPLETED
Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy
M.D. Anderson Cancer Center n=21
NCT02101268 COMPLETED
Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Sierra Oncology LLC - a GSK company n=156
NCT01969838 COMPLETED
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
Sierra Oncology LLC - a GSK company n=432
NCT01387763 COMPLETED
A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms
Thomas Stauffer Larsen n=202
NCT02055781 TERMINATED
Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia
CTI BioPharma n=311
NCT01773187 TERMINATED
Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
CTI BioPharma n=327
NCT00934544 COMPLETED
Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial
Novartis Pharmaceuticals n=219
NCT02598297 TERMINATED
Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.
Novartis Pharmaceuticals n=49
NCT01178281 COMPLETED
Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence
Celgene n=267
NCT01493414 COMPLETED
INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis.
Novartis Pharmaceuticals n=2,233
NCT02087059 COMPLETED
A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis
Novartis Pharmaceuticals n=51
NCT00799461 COMPLETED
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium n=1,337

Full Myelofibrosis Pipeline

Every sponsor, every trial across Phase 1–4. Sortable, filterable, exportable.

Unlock with Pro

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only